Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY: NVO )

75.56 +0.77 (+1.03%)
Streaming Delayed Price Updated: 1:43 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
75 76 Next >
Could Eli Lilly Beat Rivals in the Billion-Dollar Weight Loss Drug Market in 2025? Evidence Is Piling Up, and Here's What It Says.
Via The Motley Fool
Stock Market Hits Highs On Salesforce, Tech Earnings; Bitcoin Tops $100,000, Briefly: Weekly Review
Salesforce and mostly positive tech earnings buoyed the major indexes. 
Via Investor's Business Daily
Despite its growth, NYSE:NVO remains within the realm of affordability.
NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) stands out as a growth opportunity that won't break the bank. 
Via Chartmill
Amgen Stock Falls on Weight Loss Drug Data: Overreaction or Fair?
Results for Amgen's weight loss drug Maritide were highly anticipated, but fell short. However, MariTide could still turn the tables in future studies. 
Via MarketBeat
What the Options Market Tells Us About Novo Nordisk
Via Benzinga
Is Novo Nordisk Stock a Buy?
Via The Motley Fool
How Much Did Americans Overspend On Weight Loss Medications in 2024? GoodRx Reveals
GoodRx's latest research shows surging demand for weight loss medications like Wegovy and Zepbound, despite high costs and limited insurance coverage, with consumers overspending $200 million in 2024. 
Via Benzinga
2 Telehealth Stocks That Could Gain from Trump’s New FDA Pick
Discover two telehealth stocks, Hims & Hers (HIMS) and Teladoc (TDOC), poised to benefit from Trump's FDA nominee, Dr. Marty Makary, a telemedicine advocate. 
Via MarketBeat
Topics Government Lawsuit
Exposures Financial Legal Political
The Weight-Loss Battle That Could Rattle Eli Lilly's $100 Billion Market
An age-old battle in pharmaceuticals could further rattle Eli Lilly stock and its potential $100 billion market in obesity. 
Via Investor's Business Daily
This Healthcare Stock Is a Favorite of Billionaires. But Is It a Buy?
Unsurprisingly, these stock pickers are capitalizing on an opportunity that's only recently become addressable. 
Via The Motley Fool
Lilly Tops Nordisk In Weight Loss Battle
The two market-leading weight loss/obesity drugs (GLP-1), Zepabound (Eli Lilly) and Wegovy (Novo Nordisk), just completed a clinical side-by-side trial. 
Via Talk Markets
Topics Stocks / Equities
Wegovy Maker Novo Nordisk To Buy Novavax's Czech Republic Manufacturing Facility For $200 Million
Novavax sells Czech manufacturing facility to Novo Nordisk for $200 million, aiming to cut costs by $80 million annually and support its growth strategy. 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Stock Of The Day: Where Will The Eli Lilly Rally End?
Shares of Eli Lilly (LLY) are approaching a price level that had previously been a peak. There is a good chance they hit resistance at it. 
Via Benzinga
Eli Lilly's Zepbound Vs. Novo Nordisk's Wegovy - Which Shows Greater Weight Loss?
Eli Lilly's Zepbound outperformed Wegovy in weight loss and key outcomes during the SURMOUNT-5 trial, showing a comparable safety profile. 
Via Benzinga
Eli Lilly's Zepbound Beats Novo Nordisk's Wegovy In Head-To-Head Weight-Loss Trial
Lilly touted findings from the first head-to-head clinical trial. 
Via Investor's Business Daily
Eli Lilly Just Got a Bundle of Good News: Time to Buy?
Via The Motley Fool
Weight Loss Drug Wars Heat Up: Amgen Challenges Eli Lilly, Novo's Dominance
Amgen's new obesity drug, MariTide, shows promise against giants Eli Lilly and Novo Nordisk, but faces tough competition in a $100B market. 
Via Benzinga
Want To Bet On Ozempic, Wegovy Success? Defiance Introduces Leveraged ETF To Capture Novo Nordisk Momentum
Defiance ETFs introduces NVOX, a leveraged ETF offering 2X exposure to Novo Nordisk's stock price movements, targeting the booming weight loss market with tactical trading opportunities. 
Via Benzinga
Topics ETFs
Technical Monday: Novo Nordisk, A Love Story
The stock has found some buyers as we begin December. Plus, holding the 23-month MA means that the company’s stock is still in a positive 2-year business cycle expansion. 
Via Talk Markets
Topics Stocks / Equities
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Big Pharma Pushes To Revise Biden-era Medicare Drug Price Negotiation Law Under Trump
Pharma companies lobby for changes to Medicare drug price rules, targeting a four-year delay for pills' eligibility. Critics warn it may hinder patient access and innovation. 
Via Benzinga
Weight Loss Drugs Like Wegovy, Zepbound Linked To Reduced Alcohol Use: Study
A study finds that anti-obesity medications may help reduce alcohol consumption, with nearly half of participants in weight loss programs reporting decreased use. 
Via Benzinga
Down 12.3% at One Point in a Single Trading Session, Is Amgen Stock Still a Buy?
Via The Motley Fool
Viking Therapeutics Stock On Brink Of Death Cross As Weight Loss Hype Loses Momentum
Analysts are concerned about Viking's ability to compete in the lucrative obesity drug market, dominated by Eli Lilly and Novo Nordisk. 
Via Benzinga
The Ultimate Pharmaceutical Stock to Buy With $1,000 Right Now
Via The Motley Fool
Vanity Trades Moving And The Weekly Moving Average Trigger
A discussion about exponential moving average and price for our 
Via Talk Markets
Topics Stocks / Equities
Biden Proposes Medicare, Medicaid Access For Popular Weight-Loss Drugs
The Biden Administration's proposal expands Medicare and Medicaid coverage for anti-obesity drugs, cutting costs for millions while addressing the obesity crisis. 
Via Benzinga
Amgen Crashes 12% After Weight-Loss Drug Meets Eli Lilly's In A Key Test
Over the course of a year, Amgen's MariTide helped patients lose about 20% of their body weight. 
Via Investor's Business Daily
Billionaire Ken Griffin Invested $93 Million of Citadel's Portfolio in a Stock That Could Rocket 105% Higher, According to a Wall Street Analyst
Via The Motley Fool
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
75 76 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.